Katarzyna Jamieson, MD
Hematology & Oncology · Iowa City, IANPI 1376582205
Payments from drug & device makers
What this record shows
3 manufacturers reported payments, led by Sandoz at 45.9% of the total. Reporting peaked in 2019 at $125 and has fallen 82.1% since, to $23 in 2025. That places this record below the midpoint for hematology & oncology clinicians in IA, where the typical reported total is $603.
Across 3 payments — averaging $91.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sandoz$125
- Janssen Scientific Affairs, LLC$125
- Bristol Myers Squibb$23
Across 142 payments — averaging $3081.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$208K
- Astellas Pharma Global Development$98K
- National Marrow Donor Program$84K
- Sanofi US Services Inc.$25K
- Pharmacyclics LLC, An Abbvie Company$20K
- Daiichi Sankyo Inc.$3K
What the payments were for
- Grants$12546%
- Food & beverage$14854%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sandoz | 1 | $125 |
| Janssen Scientific Affairs, LLC | 1 | $125 |
| Bristol Myers Squibb | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$273 in reported general payments places this provider in the 35th percentile of 75 hematology & oncology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 44 | $685,280 |
| RezurockBelumosudil Mesylate | 13 | $386,597 |
| EliquisApixaban | 22 | $12,408 |
| JanuviaSitagliptin Phosphate | 15 | $8,142 |
| Tacrolimus | 34 | $3,363 |
| ValacyclovirValacyclovir Hcl | 57 | $1,510 |
| Dapsone | 13 | $447 |
| Hydrocortisone | 12 | $269 |
| Olanzapine | 20 | $207 |
| Acyclovir | 11 | $109 |
| Pantoprazole Sodium | 30 | $92 |
| Duloxetine Hcl | 11 | $84 |
| Prednisone | 13 | $82 |
| Gabapentin | 16 | $51 |
| Amlodipine Besylate | 21 | $43 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Iowa City
- Usha PerepuIowa City$70K
- Umang SwamiIowa City$54K
- Umar FarooqIowa City$30K
- Brian LinkIowa City$26K
- Mark KarwalIowa City$25K
- Mohammed MilhemIowa City$8K
- Laurel LyckholmIowa City$7K
- Christopher StrouseIowa City$7K
- Seth MaliskeIowa City$6K
- Douglas LauxIowa City$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.